Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INDP Indaptus Therapeutics, Inc.

Market Closed 05-22 16:00:00 EDT

1.22

+0.16

+15.09%

盘后1.24

+0.02+1.64%

19:59 EDT

High1.22	Low0.9200	Vol200.44K
Open1.11	D1 Closing1.06	Amplitude28.30%
Mkt Cap137.86M	Tradable Cap1.44M	Total Shares113.00M
T/O226.57K	T/O Rate17.00%	Tradable Shares1.18M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INDP","market":"US","secType":"STK","nameCN":"Indaptus Therapeutics, Inc.","latestPrice":1.22,"timestamp":1779480000000,"preClose":1.06,"halted":0,"volume":200444,"hourTrading":{"tag":"盘后","latestPrice":1.24,"preClose":1.22,"latestTime":"19:59 EDT","volume":722,"amount":885.4519,"timestamp":1779494355402,"change":0.02,"changeRate":0.016393,"amplitude":0.016393},"delay":0,"changeRate":0.150943396226415,"floatShares":1179100,"shares":112999999,"eps":-16.8254,"marketStatus":"Market Closed","change":0.16,"latestTime":"05-22 16:00:00 EDT","open":1.11,"high":1.22,"low":0.92,"amount":226568.26740799999,"amplitude":0.283019,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-16.8254,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"listingDate":1438660800000,"exchange":"NASDAQ","adjPreClose":1.06,"preHourTrading":{"tag":"盘前","latestPrice":1.12,"preClose":1.06,"latestTime":"09:28 EDT","volume":43934,"amount":55028.0643044,"timestamp":1779456481047,"change":0.06,"changeRate":0.056604,"amplitude":0.330189},"postHourTrading":{"tag":"盘后","latestPrice":1.24,"preClose":1.22,"latestTime":"19:59 EDT","volume":722,"amount":885.4519,"timestamp":1779494355402,"change":0.02,"changeRate":0.016393,"amplitude":0.016393},"volumeRatio":1.13569995125486},"requestUrl":"/m/hq/s/INDP/wiki","defaultTab":"wiki","newsList":[{"id":"2635927086","title":"Indaptus Therapeutics Q1 net loss narrows as expenses fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2635927086","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635927086?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:07","pubTimestamp":1778843263,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Q1 net loss narrows as expenses fallOverviewU.S. biotech firm's Q1 net loss narrowed as operating expenses declinedCompany is reassessing development priorities after executive m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL1N41S0FH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635809086","title":"Indaptus net loss narrows to $2.5 million in Q1 FY26; R&D expenses drop 82% to $491,134","url":"https://stock-news.laohu8.com/highlight/detail?id=2635809086","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635809086?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:01","pubTimestamp":1778842902,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics posted a first-quarter net loss of USD 2.54 million, narrowing from USD 4.53 million a year earlier; loss per share improved to USD 0.23 from USD 9.11.Research and development expense fell to 491,134 from USD 2.81 million a year earlier, due to lower Phase 1 clinical costs and reduced payroll tied to headcount and salary cuts.Cash and cash equivalents dropped to USD 1.5 million at March 31 from USD 8.51 million at Dec. 31; net cash used in operating activities increased to USD 7.01 million from USD 5.05 million.Management said it is reassessing development priorities and evaluating the Decoy platform’s preclinical data and scientific rationale, while reviewing operating initiatives, resource allocation, financing alternatives, and strategic options.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL5bqhJg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","BK4585","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014005.SGD","BK4588","LU2210150020.SGD","LU0314104364.USD","NDAQ","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","SG9999014013.SGD","INDP","BK4139","BK4112","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635076085","title":"Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635076085","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635076085?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:00","pubTimestamp":1778842802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA3RTD0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635850460","title":"Indaptus Therapeutics Q1 EPS USD -0.23","url":"https://stock-news.laohu8.com/highlight/detail?id=2635850460","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635850460?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:00","pubTimestamp":1778842802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX467CC4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633746837","title":"Indaptus Therapeutics Inc  expected to post a loss of $1.87 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633746837","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633746837?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:30","pubTimestamp":1778254212,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc  expected to post a loss of $1.87 a share - Earnings Preview Indaptus Therapeutics Inc INDP.OQ INDP.O is expected to  report resultson May 12 (estimated) for the period endin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1UU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630820339","title":"Indaptus amends 8-K to reflect director Johnny Fox Arrowsmith legal name change","url":"https://stock-news.laohu8.com/highlight/detail?id=2630820339","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630820339?lang=en_us&edition=fundamental","pubTime":"2026-04-25 05:01","pubTimestamp":1777064489,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics filed an amended Form 8-K to correct a director name disclosed in an April 23, 2026 report.Director previously identified as Yi Zhang  changed legal name to Johnny Fox Arrowsmith.Arrowsmith uses “Yi Zhang” as his professional name.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL6CtCMx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629775128","title":"Indaptus Therapeutics director Qinglai Lu files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2629775128","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629775128?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:06","pubTimestamp":1776715616,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics filed an initial beneficial ownership statement naming Qinglai Lu as a director, dated April 8, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL8wdD8r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624654276","title":"Indaptus Therapeutics Inc - Appoints Yu Ding as CFO Effective April 1, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624654276","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624654276?lang=en_us&edition=fundamental","pubTime":"2026-04-04 00:01","pubTimestamp":1775232081,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nFWN40L141:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624665428","title":"Indaptus Therapeutics names Yu Ding CFO after Nir Sassi resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2624665428","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624665428?lang=en_us&edition=fundamental","pubTime":"2026-04-04 00:00","pubTimestamp":1775232056,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics named Yu Ding chief financial officer effective April 1, 2026.Lu is managing partner at Plunkett Capital, with prior senior roles in private banking at Goldman Sachs in Asia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL1w5rJD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443382.USD","LU0251131958.USD","IE0004091025.USD","LU1868836591.USD","LU2750360997.AUD","BK4585","LU0345770993.USD","IE0034235188.USD","LU0345770308.USD","LU0106831901.USD","IE00B19Z3581.USD","BK4139","BK4516","BK4504","LU2237443622.USD","LU2471134523.USD","LU2237443895.HKD","LU1868836757.USD","LU2265009873.SGD","LU0742534661.SGD","BK4127","LU1868836914.USD","GSX","IE00BFXG1179.USD","LU1668664300.SGD","IE0004086264.USD","LU2237443978.SGD","LU1894683348.USD","LU0048573561.USD","IE00BSNM7G36.USD","INDP","LU2750360641.GBP","IE00B19Z3B42.SGD","LU0096364046.USD","BK4533","LU2471134879.HKD","LU2471134796.USD","BK4550","IE0002270589.USD","LU2237443549.SGD","LU2471134952.CNY","LU0061475181.USD","LU2237438978.USD","LU2237443465.HKD","LU0251142724.SGD","LU1791807156.HKD","LU1868837136.USD","LU1868837300.USD","BK4552","LU1894683264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624633894","title":"Indaptus Therapeutics files Form 3; Sino Lion Ventures reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2624633894","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624633894?lang=en_us&edition=fundamental","pubTime":"2026-04-03 07:17","pubTimestamp":1775171848,"startTime":"0","endTime":"0","summary":"Sino Lion Ventures filed a Form 3 disclosing beneficial ownership of 38,895,000 Indaptus Therapeutics common shares.Filing identifies Sino Lion Ventures as a 10% owner of Indaptus.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL9G5BBv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624633893","title":"Indaptus Therapeutics files Form 3 for CEO Junyi Dai initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624633893","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624633893?lang=en_us&edition=fundamental","pubTime":"2026-04-03 07:16","pubTimestamp":1775171772,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics CEO Junyi Dai reported ownership of 11,250,000 common shares in an initial SEC filing dated March 23, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLddcl7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622984838","title":"Indaptus Therapeutics FY2025 annual report published; net loss widens to $21 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622984838","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622984838?lang=en_us&edition=fundamental","pubTime":"2026-03-27 02:10","pubTimestamp":1774548653,"startTime":"0","endTime":"0","summary":"Indaptus said it is evaluating strategic options for a post-investment transaction involving an investment in or acquisition of an operating business.David Lazar invested USD 6.0 million through purchases of Series AA and Series AAA preferred stock, and the preferred stock is convertible into 111,000,000 shares of common stock.A special stockholder meeting approved increasing authorized common shares to 1,000,000,000 and approved a reverse stock split range to be set by the board.The company ended enrollment in its Decoy20 monotherapy dosing and later discontinued enrollment in the Decoy20 combination study with BeOne’s anti-PD-1 antibody tislelizumab, with no participants remaining.Indaptus reported a warrant repricing that reduced exercise prices on certain warrants to USD 1.75.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLbWWw6h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622013145","title":"Indaptus investors group discloses 96.2% beneficial ownership after preferred conversion","url":"https://stock-news.laohu8.com/highlight/detail?id=2622013145","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622013145?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:31","pubTimestamp":1774384306,"startTime":"0","endTime":"0","summary":"Indaptus said David Lazar sold rights in 700,000 shares of Series AAA preferred stock and 196,800 shares of Series AA preferred stock to five purchasers for USD 11.2 million.Assuming conversion of the preferred stock, Yun Yao would beneficially own 37.08% of the company’s common shares.Sino Lion Ventures would beneficially own 34.35% on the same basis.The purchasers said they plan to file a joint Schedule 13D and may be deemed a group, while each purchaser reported sole voting and dispositive power over its own shares.After conversion, David Lazar’s ownership would be about 1.82% of the outstanding common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate thi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL7dzcVN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620340352","title":"Indaptus Therapeutics FY2025 net loss widens 38.8% to USD 20.85 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620340352","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620340352?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:35","pubTimestamp":1773779738,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025. The company reported a net loss of USD 20.85 million, compared with a net loss of USD 15.02 million a year earlier. Research and development expense rose 28.8% to USD 9.34 million, driven mainly by higher Phase 1 clinical trial costs and higher payroll and related expenses. General and administrative expense increased 29.3% to USD 10.49 million, reflecting higher payroll and transaction-related expenses, partly offset by lower D&O insurance, investor relations and board fees. Cash and cash equivalents were USD 8.5 million at year-end, and management said it expects this to fund operating needs into the second quarter of 2026 while it pursues a strategic transaction, after discontinuing enrollment in its Decoy20 Combination Study and stating it has no current plans to initiate a new clinical trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL7NBnrZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617263837","title":"Indaptus Therapeutics Inc  expected to post a loss of $4.36 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2617263837","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617263837?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:15","pubTimestamp":1772802906,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc  expected to post a loss of $4.36 a share - Earnings Preview Indaptus Therapeutics Inc INDP.OQ INDP.O is expected to  show no change in quarterly revenue when it reports  res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL8N3ZU1CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614862439","title":"Indaptus Therapeutics Wins Approval for Reverse Stock Split Authority","url":"https://stock-news.laohu8.com/highlight/detail?id=2614862439","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614862439?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:09","pubTimestamp":1772226552,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. said shareholders approved a proposal authorizing its board to implement up to two reverse stock splits of the company’s common stock, with an aggregate split ratio ranging from 1-for-2 to 1-for-199. The final ratio and timing will be determined by the board and carried out through an amendment to the company’s certificate of incorporation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL1qYX1L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614162862","title":"Indaptus Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Jerome D. Jabbour","url":"https://stock-news.laohu8.com/highlight/detail?id=2614162862","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614162862?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:06","pubTimestamp":1772226407,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics, Inc. filed an initial statement of beneficial ownership  naming Jerome D. Jabbour, Director, as the reporting person. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL4YZMwd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614264490","title":"Indaptus Therapeutics Director Matthew Charles McMurdo Files Initial Statement of Beneficial Ownership (Form 3)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614264490","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614264490?lang=en_us&edition=fundamental","pubTime":"2026-02-26 23:57","pubTimestamp":1772121459,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics, Inc. filed an initial statement of beneficial ownership reporting that Matthew Charles McMurdo, a Director, beneficially owns company securities. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL556z8S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610192204","title":"Indaptus Therapeutics Cuts Warrant Exercise Prices to $1.75 in Unregistered Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2610192204","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610192204?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:31","pubTimestamp":1770906664,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. announced that it has entered into agreements to reprice certain outstanding warrants originally issued in financing rounds during 2024 and 2025. The exercise prices of these warrants, covering an aggregate of 913,638 shares of common stock, were reduced to $1.75 per share, in line with Nasdaq’s minimum price rules. In connection with this repricing, holders agreed to vote their shares in favor of all proposals at the upcoming special stockholder meeting. Additionally, the company’s board of directors unilaterally reduced the exercise prices of remaining warrants and placement agent warrants for 762,787 shares to $1.75 per share. These transactions constitute unregistered sales of equity securities. All other warrant terms remain unchanged.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL6JpD5R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605436149","title":"Indaptus Therapeutics Cuts Executive Officer Salaries to $60,000 Per Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2605436149","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605436149?lang=en_us&edition=fundamental","pubTime":"2026-01-21 05:08","pubTimestamp":1768943302,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. has announced adjustments to the compensation of its executive officers. Effective January 15, 2026, the annual salaries of Co-Chief Executive Officer Jeffrey A. Meckler and Chief Science Officer Michael J. Newman have been set at $60,000 for the remainder of the year, as outlined in newly executed salary adjustment agreements. These agreements follow previous employment modifications related to the company's securities purchase agreement with investor David E. Lazar.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL4dYjPD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.indaptusrx.com","stockEarnings":[{"period":"1week","weight":-0.2327},{"period":"1month","weight":-0.6453},{"period":"3month","weight":-0.396},{"period":"6month","weight":-0.3405},{"period":"1year","weight":-0.8852},{"period":"ytd","weight":-0.5808}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.037296},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.000875},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.06305},{"month":4,"riseRate":0.363636,"avgChangeRate":0.020664},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.102035},{"month":6,"riseRate":0.5,"avgChangeRate":-0.001521},{"month":7,"riseRate":0.4,"avgChangeRate":-0.067711},{"month":8,"riseRate":0.4,"avgChangeRate":0.036746},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.055501},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.090558},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.057102},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.026598}],"exchange":"NASDAQ","name":"Indaptus Therapeutics, Inc.","nameEN":"Indaptus Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Indaptus Therapeutics, Inc.(INDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Indaptus Therapeutics, Inc.,INDP,Indaptus Therapeutics, Inc.股票,Indaptus Therapeutics, Inc.股票老虎,Indaptus Therapeutics, Inc.股票老虎国际,Indaptus Therapeutics, Inc.行情,Indaptus Therapeutics, Inc.股票行情,Indaptus Therapeutics, Inc.股价,Indaptus Therapeutics, Inc.股市,Indaptus Therapeutics, Inc.股票价格,Indaptus Therapeutics, Inc.股票交易,Indaptus Therapeutics, Inc.股票购买,Indaptus Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Indaptus Therapeutics, Inc.(INDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction